Findings from a large US study suggest that early treatment with antibiotics is not associated with improved outcomes among patients hospitalised for asthma exacerbation and treated with systemic corticosteroids.
Patients with asthma who are treated with the once-daily inhaled corticosteroid/long-acting beta agonist regimen fluticasone furoate/vilanterol have better treatment adherence than those taking the twice-daily budesonide/formoterol combination, researchers report.
A genome-wide association study has identified novel genetic variants associated with the risk of developing moderate-to-severe asthma, a substantial proportion of which are also associated with mild asthma susceptibility.
Findings from the TROPOS trial indicate that treatment with the interleukin-13-targeted monoclonal antibody tralokinumab does not decrease corticosteroid use among patients with severe uncontrolled asthma.
The anti-interleukin-5 monoclonal antibody mepolizumab has durable safety and efficacy profiles over an average 3.5 years of follow-up in patients with severe eosinophilic asthma, indicate findings from the COLUMBA open-label extension study.